OBJECTIVE: The objective was to assess the analgesic, antihyperesthesic, and anti-allodynic properties of @entity28585 in @entity9 . DESIGN: We describe a @entity1 with refractory, severe @entity158 successfully treated with @entity28585 in an open-label, baseline-controlled Phase I/II trial. SETTING: The @entity1 was hospitalized for treatment and observation. @entity1 : The @entity1 was a 43-year-old @entity1 with intractable @entity158 of 23 years' duration secondary to @entity5300 . INTERVENTION: @entity28585 , the first neuron-specific, N-type, voltage-sensitive @entity460 channel blocker developed for clinical use, was administered by continuous, constant-rate, intrathecal infusion via an indwelling cervical catheter. OUTCOME MEASURES: The primary outcome measures were the Visual Analog Scales of @entity158 Intensity (VASPI) and @entity158 Relief (VASPR). RESULTS: The @entity1 experienced complete @entity158 relief (VASPI = 0.0 cm and VASPR = 10.0 cm) with elimination of hyperesthesia and @entity1931 . CONCLUSIONS: @entity28585 , administered intrathecally by continuous, constant-rate infusion, produced dose-dependent @entity158 relief in a 43-year-old male @entity1 with a 23-year history of intractable deafferentation and phantom limb @entity158 secondary to @entity5300 and subsequent amputation. @entity227 , and lateral-gaze nystagmus were dose-dependent side effects that resolved with decreasing dose levels. Complete @entity158 relief was achieved in this @entity1 without side effects after dose adjustment. We conclude that @entity28585 is a potent analgesic, antihyperesthesic, and antiallodynic agent. Controlled studies of @entity28585 in @entity1 with malignant and nonmalignant @entity158 syndromes are warranted and are under way.

Use of intrathecal XXXX , a novel, N-type, voltage-sensitive, @entity460 channel blocker, in the management of intractable @entity5300 pain.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man', 'PATIENT'] @entity227 :: ('MESH:D014786', 'Disease') :: ['Dizziness, blurred vision'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia'] @entity5300 :: ('MESH:D020516', 'Disease') :: ['brachial plexus avulsion'] @entity28585 :: ('MESH:C078452', 'Chemical') :: ['SNX-111'] @entity158 :: ('MESH:D010146', 'Disease') :: ['deafferentation pain', 'Pain', 'pain'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']
@entity28585 :: (MESH:C078452,Chemical) :: ['SNX-111']
